Understanding the response to immunotherapy in humans

Ena Wang, Monica C. Panelli, Francesco M. Marincola

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Whether the efforts of the last decade aimed at the development of vaccines against tumor-specific antigens encountered success or failure is a matter of expectations. On the bright side, we could optimistically observe that anti-cancer-vaccines stand as an outstanding example of the successful implementation of modern biotechnology tools for the development of biologically sound therapeutics. In particular, vaccines against melanoma (the prototype model of tumor immunology in humans) can reproducibly induce cytotoxic T cell (CTL) responses exquisitely specific for cancer cells. This achievement trespasses the specificity of any other anti-cancer therapy. The skeptics, on the other end, might point out that immunization only rarely leads to cancer regression, labeling, therefore, this approach is ineffective. In our opinion this judgment stems from the naïve expectation that CTL induction is sufficient for an effective immune response. Here we propose that more needs to be understood about the mechanisms required for the induction of a therapeutically relevant immune response in humans. In particular, we will discuss the variables related to cancer heterogeneity, the weight of individual patients' polymorphism(s), the role of the T cell activation and differentiation and, finally, the complex relationship between immune and cancer cells within the tumor microenvironment.

Original languageEnglish
Pages (from-to)105-117
Number of pages13
JournalSpringer Seminars in Immunopathology
Volume27
Issue number1
DOIs
Publication statusPublished - Jun 2005
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
T-Lymphocytes
Vaccines
Cancer Vaccines
Tumor Microenvironment
Neoplasm Antigens
Biotechnology
Allergy and Immunology
Cell Differentiation
Melanoma
Immunization
Weights and Measures
Therapeutics

Keywords

  • Immunization
  • Immunotherapy
  • Interleukin-2
  • Melanoma

ASJC Scopus subject areas

  • Immunology

Cite this

Understanding the response to immunotherapy in humans. / Wang, Ena; Panelli, Monica C.; Marincola, Francesco M.

In: Springer Seminars in Immunopathology, Vol. 27, No. 1, 06.2005, p. 105-117.

Research output: Contribution to journalReview article

Wang, Ena ; Panelli, Monica C. ; Marincola, Francesco M. / Understanding the response to immunotherapy in humans. In: Springer Seminars in Immunopathology. 2005 ; Vol. 27, No. 1. pp. 105-117.
@article{c8e32f9f320d449a8afa1ccded1e17e4,
title = "Understanding the response to immunotherapy in humans",
abstract = "Whether the efforts of the last decade aimed at the development of vaccines against tumor-specific antigens encountered success or failure is a matter of expectations. On the bright side, we could optimistically observe that anti-cancer-vaccines stand as an outstanding example of the successful implementation of modern biotechnology tools for the development of biologically sound therapeutics. In particular, vaccines against melanoma (the prototype model of tumor immunology in humans) can reproducibly induce cytotoxic T cell (CTL) responses exquisitely specific for cancer cells. This achievement trespasses the specificity of any other anti-cancer therapy. The skeptics, on the other end, might point out that immunization only rarely leads to cancer regression, labeling, therefore, this approach is ineffective. In our opinion this judgment stems from the na{\"i}ve expectation that CTL induction is sufficient for an effective immune response. Here we propose that more needs to be understood about the mechanisms required for the induction of a therapeutically relevant immune response in humans. In particular, we will discuss the variables related to cancer heterogeneity, the weight of individual patients' polymorphism(s), the role of the T cell activation and differentiation and, finally, the complex relationship between immune and cancer cells within the tumor microenvironment.",
keywords = "Immunization, Immunotherapy, Interleukin-2, Melanoma",
author = "Ena Wang and Panelli, {Monica C.} and Marincola, {Francesco M.}",
year = "2005",
month = "6",
doi = "10.1007/s00281-004-0198-7",
language = "English",
volume = "27",
pages = "105--117",
journal = "Seminars in Immunopathology",
issn = "1863-2297",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Understanding the response to immunotherapy in humans

AU - Wang, Ena

AU - Panelli, Monica C.

AU - Marincola, Francesco M.

PY - 2005/6

Y1 - 2005/6

N2 - Whether the efforts of the last decade aimed at the development of vaccines against tumor-specific antigens encountered success or failure is a matter of expectations. On the bright side, we could optimistically observe that anti-cancer-vaccines stand as an outstanding example of the successful implementation of modern biotechnology tools for the development of biologically sound therapeutics. In particular, vaccines against melanoma (the prototype model of tumor immunology in humans) can reproducibly induce cytotoxic T cell (CTL) responses exquisitely specific for cancer cells. This achievement trespasses the specificity of any other anti-cancer therapy. The skeptics, on the other end, might point out that immunization only rarely leads to cancer regression, labeling, therefore, this approach is ineffective. In our opinion this judgment stems from the naïve expectation that CTL induction is sufficient for an effective immune response. Here we propose that more needs to be understood about the mechanisms required for the induction of a therapeutically relevant immune response in humans. In particular, we will discuss the variables related to cancer heterogeneity, the weight of individual patients' polymorphism(s), the role of the T cell activation and differentiation and, finally, the complex relationship between immune and cancer cells within the tumor microenvironment.

AB - Whether the efforts of the last decade aimed at the development of vaccines against tumor-specific antigens encountered success or failure is a matter of expectations. On the bright side, we could optimistically observe that anti-cancer-vaccines stand as an outstanding example of the successful implementation of modern biotechnology tools for the development of biologically sound therapeutics. In particular, vaccines against melanoma (the prototype model of tumor immunology in humans) can reproducibly induce cytotoxic T cell (CTL) responses exquisitely specific for cancer cells. This achievement trespasses the specificity of any other anti-cancer therapy. The skeptics, on the other end, might point out that immunization only rarely leads to cancer regression, labeling, therefore, this approach is ineffective. In our opinion this judgment stems from the naïve expectation that CTL induction is sufficient for an effective immune response. Here we propose that more needs to be understood about the mechanisms required for the induction of a therapeutically relevant immune response in humans. In particular, we will discuss the variables related to cancer heterogeneity, the weight of individual patients' polymorphism(s), the role of the T cell activation and differentiation and, finally, the complex relationship between immune and cancer cells within the tumor microenvironment.

KW - Immunization

KW - Immunotherapy

KW - Interleukin-2

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=21344467279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344467279&partnerID=8YFLogxK

U2 - 10.1007/s00281-004-0198-7

DO - 10.1007/s00281-004-0198-7

M3 - Review article

VL - 27

SP - 105

EP - 117

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

SN - 1863-2297

IS - 1

ER -